Clinical trial
A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
NCT06247787 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
- Lead sponsor
- Children's Oncology Group
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 4, 2025
- Completion date
- March 31, 2028
- Enrollment
- 36 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent childhood acute myeloid leukemia, recurrent childhood myelodysplastic syndrome, recurrent juvenile myelomonocytic leukemia, refractory childhood acute myeloid leukemia, refractory childhood myelodysplastic syndrome, refractory juvenile myelomonocytic leukemia